NEWARK, Calif., Dec. 3, 2021 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company")
today announced that Dinesh V.
Patel, Ph.D., President and Chief Executive Officer, will
present at the upcoming JMP Securities Hematology and Oncology
Summit taking place virtually on December 6,
2021.
Presentation details:
Date: Monday, December 6, 2021
Time: 1:40 p.m. EST
A webcast of the event will be available for 90 days on the
Investors section of the Protagonist Therapeutics website at
http://investors.protagonist-inc.com/.
About Protagonist Therapeutics
Protagonist Therapeutics is a biopharmaceutical company with
multiple peptide-based investigational new chemical entities in
different stages of development, all derived from the Company's
proprietary technology platform.
Protagonist's pipeline includes rusfertide (PTG-300), an
investigational, injectable hepcidin mimetic currently in a Phase 2
proof-of-concept clinical trial for polycythemia vera (PV), a Phase
2 study in PV subjects with high hematocrit levels, and a recently
completed Phase 2a study for hereditary hemochromatosis. The
Company plans to initiate a single, global Phase 3 randomized,
placebo-controlled polycythemia vera trial evaluating the efficacy
and safety of a once weekly, subcutaneously self-administered dose
of rusfertide.
The Company is also evaluating an orally delivered,
gut-restricted alpha-4-beta-7 integrin specific antagonist peptide
(PN-943) currently in a Phase 2 study in adults with moderate to
severe active ulcerative colitis (UC). The Company is targeting
ulcerative colitis as the initial indication.
The Company has a worldwide license and collaboration agreement
with Janssen Biotech, Inc., for the development of oral peptide
IL-23 receptor antagonists. Compounds in development include
PN-235, a second-generation oral interleukin-23 receptor antagonist
candidate. Under the collaboration with Janssen, PN-235 is expected
to advance into Phase 2 studies in psoriasis and new Phase 2
clinical studies in inflammatory bowel diseases.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-jmp-securities-hematology-and-oncology-summit-301436894.html
SOURCE Protagonist Therapeutics, Inc.